EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MASLD coexisting with PCOS increases cardiometabolic risk

Oyekoya T Ayonrinde iD, Trevor A Mori, Leon A Adams, Lawrence J Beilin iD, John K Olynyk, Roger Hart iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Oyekoya T Ayonrinde und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, The University of Western Australia, Nedlands, WA 6009, Australia. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Future Health Research and Innovation Fund, Spinnaker Health Research Foundation, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In women in their reproductive years, metabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) are the most common chronic liver and endocrine disorders, respectively. MASLD and PCOS are associated with longer-term risk of cardiometabolic complications. We aimed to determine whether PCOS coexisting with MASLD (PCOS + MASLD) predicts greater risk of future cardiometabolic adverse parameters than either condition alone after 10 years in a longitudinal study of adolescents in the Raine Study.

Method

A total of 199 community-based female adolescents participating in the Raine Study had assessments for both PCOS and MASLD, including anthropometry, blood tests, and pelvic and abdominal ultrasound. Using updated diagnostic criteria, diagnoses of PCOS at age 14 years and MASLD at age 17 years, were retrospectively determined. At age 27 years, 148 participants had further anthropometry and cardiovascular and fasting blood assessments.

Results

At age 17 years, 37 (18.6%) had MASLD, 32 (16.1%) had PCOS, 20 (10.1%) had PCOS without MASLD, and 142 (71.4%) had neither. Among adolescents with PCOS, 12/32 (37.5%) had PCOS + MASLD, associated with obesity, higher serum remnant lipoprotein cholesterol, and free and total testosterone, but lower SHBG, compared with those with only MASLD, PCOS, or neither (P < .05 for all). By age 27 years, those with PCOS + MASLD (10/148) during adolescence were more insulin resistant and had higher serum remnant lipoprotein cholesterol and triglyceride/high-density lipoprotein cholesterol ratio (P < .05 for all), compared with those with only PCOS or MASLD or neither. PCOS without MASLD or obesity in adolescence did not predict future insulin resistance.

Conclusion

PCOS + MASLD in adolescents, but not PCOS alone, increases the likelihood of obesity, insulin resistance and an adverse cardiometabolic phenotype during adulthood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeCardiovascular DiseasesHumansFemaleAdolescentInsulin ResistanceCardiometabolic Risk FactorsAdultLongitudinal StudiesRetrospective StudiesYoung AdultObesity

Stichwörter der Autor:innen

Raine studyinsulin resistancemetabolic dysfunction-associated steatotic liver diseaseobesitypolycystic ovary syndrometestosterone

Autor:innen und Institutionen

  • Medical School, The University of Western Australia, Nedlands, WA 6009, Australia.
  • Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA 6150, Australia.
  • Medical School, Curtin University, Bentley, WA 6102, Australia.
  • Curtin Medical Research Institute, Curtin University, Bentley, WA 6102, Australia.
  • Department of Obstetrics and Gynaecology, King Edward Memorial Hospital, Subiaco, WA 6008, Australia.

ORCID-Profile: Oyekoya T Ayonrinde, Lawrence J Beilin, Roger Hart

Förderung

  • Future Health Research and Innovation Fund
  • Spinnaker Health Research Foundation
  • National Health and Medical Research Council
  • Gastroenterological Society of Australia
  • Fremantle Hospital
  • Wellcome Trust
  • National Heart Foundation
  • Royal Perth Hospital Medical Research Foundation

Zitieren

APA

Ayonrinde, O. T., Mori, T. A., Adams, L. A., Beilin, L. J., Olynyk, J. K., & Hart, R. (2026). MASLD coexisting with PCOS increases cardiometabolic risk. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag008

Vancouver

Ayonrinde OT, Mori TA, Adams LA, Beilin LJ, Olynyk JK, Hart R. MASLD coexisting with PCOS increases cardiometabolic risk. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag008

BibTeX
@article{Ayonrinde2026,
  author = {Ayonrinde, Oyekoya T and Mori, Trevor A and Adams, Leon A and Beilin, Lawrence J and Olynyk, John K and Hart, Roger},
  title = {MASLD coexisting with PCOS increases cardiometabolic risk},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag008}
}
Kostenlos starten →